Fig. 4: The loss of HAT1 expression leads to the activation of alternative signaling pathways, which contribute to BRAFi resistance in melanoma cells. | Oncogenesis

Fig. 4: The loss of HAT1 expression leads to the activation of alternative signaling pathways, which contribute to BRAFi resistance in melanoma cells.

From: Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R

Fig. 4

a Heatmap for A375 cells, expressing non-targeting (NT) or HAT1 sgRNAs. b Heatmap for A375 cells, expressing nonspecific (NS) or HAT1 shRNAs. c. Heatmap for SKMEL-28 cells, expressing NS or HAT1 shRNAs. d Venn diagram showing the genes that were significantly up- and downregulated in A375 HAT1 knockout (KO), A375 HAT1 knockdown (KD), and SKMEL-28 HAT1 KD cells in the Ras, MAPK, Wnt, and TGF-β signaling pathways. e Fold changes of the genes associated with the Ras, MAPK, TGF-β, and Wnt signaling pathways that were significantly altered in A375 cells expressing NT or HAT1 sgRNAs, A375 cells expressing NS or HAT1 shRNAs, and SKMEL-28 cells expressing NS or HAT1 shRNAs. Data are presented as the mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, calculated using Student’s t test.

Back to article page